The basics of PET molecular imaging in neurodegenerative disorders with dementia and/or parkinsonism

Positron emission tomography (PET) imaging biomarkers have become crucial in understanding and diagnosing neurodegenerative disorders. PET imaging allows for the in vivo quantification of molecular targets with high sensitivity, aiding in the study of disease pathophysiology and progression from pre...

ver descrição completa

Detalhes bibliográficos
Autores: Bronte, A. (Angela)|||/items/58668c6c-6021-4220-9d5f-8c1ad2435e8f, Prieto-Azcárate, E. (Elena)|||/items/98983a2a-3ce1-471b-8174-68cd47fc9fcb, Quincoces-Fernández, G. (Gemma)|||/items/fa93ac37-c637-4dad-be78-c9a892ebb80d, Erro-Aguirre, M.E (María Elena)|||/items/349b8d34-8ecb-40a0-bfa7-3697cd149f69, Arbizu, J. (Javier)|||/items/41665d76-74c1-4652-acb9-a98cba4ddd0b
Formato: artículo
Fecha de publicación:2025
País:España
Recursos:Universidad de Navarra
Repositorio:Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:inglés
OAI Identifier:oai:dadun.unav.edu:10171/116198
Acesso em linha:https://hdl.handle.net/10171/116198
Access Level:acceso abierto
Palavra-chave:Brain diseases
Molecular imaging
Positron Emission Tomography
Single photon emission computed tomography
Descrição
Resumo:Positron emission tomography (PET) imaging biomarkers have become crucial in understanding and diagnosing neurodegenerative disorders. PET imaging allows for the in vivo quantification of molecular targets with high sensitivity, aiding in the study of disease pathophysiology and progression from preclinical stages. By visualising specific molecular pathologies, PET biomarkers enable a shift from symptom-based to biology-based definitions of neurodegenerative diseases, allowing for earlier and more accurate detection and diagnosis. This has significant implications for developing and testing new therapies aimed at modifying disease course. In this review, we will go through the standards of PET imaging in the evaluation of neurodegenerative disorders. Specifically, we will review PET molecular imaging of amyloid-β plaques, tau pathology, as well as the effect of neurodegeneration on neuronal activity in different disorders. Moreover, we will revise PET tracers targeting neurotransmitter systems such as the dopaminergic system which can detect early functional changes in movement disorders. Issues related to methods, image interpretation, normal findings and mimics will be an important part of this review.